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L E T T E R  T O  T H E  E D I T O R
Statins and non‐alcoholic fatty liver disease
Dear Editor,
In April 9 issue, van den Berg et al1 report interesting results on 
the indication for lipid‐lowering treatment in a large cohort with 
suspected non‐alcoholic fatty liver disease (NAFLD) within the 
population‐based	Lifelines	Cohort	Study.	Fatty	liver	index	(FLI)	≥60	
was used as a proxy of NAFLD and the NAFLD fibrosis score (NFS) 
to identify the NAFLD patients with suspected advanced fibrosis. 
Cardiovascular	 disease	 (CVD)	 risk	 was	 established	 by	 the	 2016	
European society of Cardiology/European Atherosclerosis Society 
(ESC/EAS) Guidelines for the Management of Dyslipidemias.2
Subjects	with	FLI	≥	60	 (suspected	NAFLD)	had	an	 increased	10‐
year	predicted	 cardiovascular	 risk	 compared	 to	 those	with	FLI	<	60	
with an approximately 2 times higher need for statin therapy based 
on CVD risk prediction and their LDL cholesterol level. Subjects with 
a	 FLI	 ≥	 60	 were	 more	 likely	 to	 be	 classified	 with	 type	 2	 diabetes,	
Metabolic Syndrome (MetS), history of CVD and impaired renal func‐
tion. Interestingly, estimated 10‐year very high cardiovascular risk was 
approximately	4	times	higher	in	subjects	with	a	NFS	>	0.676	compared	
to those with the absence of advanced fibrosis. Finally, indication for 
statin	treatment	was	positively	associated	with	a	FLI	≥	60	after	con‐
trolling for age, sex, current smoking, impaired renal function, and the 
presence of MetS and its individual components. The above results 
have an even greater relevance if we consider that all the subjects who 
were already on statin therapy were subtracted from the analysis.
These findings may have an important clinical relevance and em‐
phasize the need for effective treatment with statins in patients with 
NAFLD. Indeed, accumulating evidence suggests that CVD, rather 
than liver disease, dictates the outcomes in NAFLD.3 Besides, in 
most subjects NAFLD constitutes the hepatic component of MetS 
and numerous patients have atherogenic dyslipidemia.
This study further supports the results of a previous study by our 
group where under prescription of statins in patients with NAFLD 
was observed.4 In fact, mild liver enzyme elevation remains a con‐
cern and despite its proven efficacy and safety,5 statin administra‐
tion is sometimes limited by the worry about related side effects. 
Indeed, there is a tendency of general physicians to discourage statin 
use in patients with baseline elevation of serum liver enzymes and/
or to discontinue medication when minor alterations were appreci‐
ated. Of note, in our study, statin under‐use was high also in patients 
at very high CV risk such as those with a previous CV event.
This study by van den Berg et al further stresses the issue of 
under prescription of statins in people with NAFLD and indication 
for treatment, based on CV risk class and low‐density lipoprotein 
cholesterol target according to ESC/EAS guidelines.
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